Savara reports fourth quarter and year end 2024 financial results and provides business update

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending december 31, 2024 and provided a business update. “completing submission of the bla is an important milestone in potentially addressing the significant unmet need of people living with apap, a rare and debilitating lung disease,” said matt pauls, chair and chief executive.
SVRA Ratings Summary
SVRA Quant Ranking